Valeant Posts $973M Net Loss in Q3

Company News

Nanaimo Daily News reported that Valeant (TSX:VRX, NYSE:VRX) recorded a net loss of $973 million, or $2.92 per share, in its third quarter due to one-time impairment and restructuring charges and the settlement of a dispute with California-based Anacor Pharmaceuticals.

Nanaimo Daily News reported that Valeant (TSX:VRX, NYSE:VRX) recorded a net loss of $973 million, or $2.92 per share, in its third quarter due to one-time impairment and restructuring charges and the settlement of a dispute with California-based Anacor Pharmaceuticals.

As quoted in the market news:

Valeant (TSX:VRX) announced earlier this week that it has agreed to pay $142.5 million to settle all outstanding disputes with Anacor Pharmaceuticals of Palo Alto, Calif.

The payment includes a previously announced $100-million arbitration award to Anacor (Nasdaq:ANAC), relating to a breach of services provided by Dow Pharmaceutical Sciences Inc. before it was bought by Valeant.

Read the full story on Nanaimo Daily News here

 

The Conversation (0)
MARKETS
COMMODITIES
CURRENCIES
Ă—